{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:31:39Z","timestamp":1791981099107,"version":"4.4.0"},"reference-count":128,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,2,19]],"date-time":"2023-02-19T00:00:00Z","timestamp":1676764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Proyectos de Generaci\u00f3n de Conocimiento","award":["PID2021-123167OB-I00"],"award-info":[{"award-number":["PID2021-123167OB-I00"]}]},{"name":"Proyectos de Generaci\u00f3n de Conocimiento","award":["RYC2020-028884-I"],"award-info":[{"award-number":["RYC2020-028884-I"]}]},{"name":"Ram\u00f3n y Cajal","award":["PID2021-123167OB-I00"],"award-info":[{"award-number":["PID2021-123167OB-I00"]}]},{"name":"Ram\u00f3n y Cajal","award":["RYC2020-028884-I"],"award-info":[{"award-number":["RYC2020-028884-I"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Pulmonary arterial hypertension (PAH) is a severe condition with a high mortality rate despite advances in diagnostic and therapeutic strategies. In recent years, significant scientific progress has been made in the understanding of the underlying pathobiological mechanisms. Since current available treatments mainly target pulmonary vasodilation, but lack an effect on the pathological changes that develop in the pulmonary vasculature, there is need to develop novel therapeutic compounds aimed at antagonizing the pulmonary vascular remodeling. This review presents the main molecular mechanisms involved in the pathobiology of PAH, discusses the new molecular compounds currently being developed for the medical treatment of PAH and assesses their potential future role in the therapeutic algorithms of PAH.<\/jats:p>","DOI":"10.3390\/ijms24044147","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T04:28:57Z","timestamp":1676867337000},"page":"4147","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Novel Molecular Mechanisms Involved in the Medical Treatment of Pulmonary Arterial Hypertension"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0889-1608","authenticated-orcid":false,"given":"Irene","family":"Martin de Miguel","sequence":"first","affiliation":[{"name":"Pulmonary Hypertension Multidisciplinary Unit, Cardiology Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (i+12), 28041 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3851-4037","authenticated-orcid":false,"given":"Alejandro","family":"Cruz-Utrilla","sequence":"additional","affiliation":[{"name":"Pulmonary Hypertension Multidisciplinary Unit, Cardiology Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (i+12), 28041 Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9340-882X","authenticated-orcid":false,"given":"Eduardo","family":"Oliver","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain"},{"name":"Centro de Investigaciones Biol\u00f3gicas Margarita Salas (CIB-CSIC), 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6640-4839","authenticated-orcid":false,"given":"Pilar","family":"Escribano-Subias","sequence":"additional","affiliation":[{"name":"Pulmonary Hypertension Multidisciplinary Unit, Cardiology Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (i+12), 28041 Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1801900","DOI":"10.1183\/13993003.01900-2018","article-title":"Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: An update","volume":"53","author":"Noordegraaf","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMra2000348","article-title":"Pulmonary Arterial Hypertension","volume":"385","author":"Hassoun","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1378\/chest.11-1460","article-title":"An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry","volume":"142","author":"Benza","year":"2012","journal-title":"Chest"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/17476348.2021.1878027","article-title":"Recent advances in the management of pulmonary arterial hypertension: Lessons from the upfront combination of ambrisentan and tadalafil","volume":"15","author":"Subias","year":"2021","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1093\/eurheartj\/ehx257","article-title":"A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension","volume":"39","author":"Kylhammar","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1700740","DOI":"10.1183\/13993003.00740-2017","article-title":"Mortality in pulmonary arterial hypertension: Prediction by the 2015 European pulmonary hypertension guidelines risk stratification model","volume":"50","author":"Hoeper","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"00854-2020","DOI":"10.1183\/23120541.00854-2020","article-title":"Early risk prediction in idiopathic versus connective tissue disease-associated pulmonary arterial hypertension: Call for a refined assessment","volume":"7","author":"Hjalmarsson","year":"2021","journal-title":"ERJ Open Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/CIRCULATIONAHA.109.911818","article-title":"Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era","volume":"122","author":"Humbert","year":"2010","journal-title":"Circulation"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/S2213-2600(22)00290-9","article-title":"Phenotypes of idiopathic pulmonary arterial hypertension","volume":"10","year":"2022","journal-title":"Lancet Respir Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMra040291","article-title":"Treatment of Pulmonary Arterial Hypertension","volume":"351","author":"Humbert","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension","volume":"373","author":"Frost","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the Treatment of Pulmonary Arterial Hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_15","first-page":"394","article-title":"A meta-analysis of randomized controlled trials in pulmonary arterial hypertension","volume":"30","author":"Manes","year":"2009","journal-title":"Eur. Heart J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMc051946","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Ghofrani","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1801887","DOI":"10.1183\/13993003.01887-2018","article-title":"Pathology and pathobiology of pulmonary hypertension: State of the art and research perspectives","volume":"53","author":"Humbert","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7265487","DOI":"10.1155\/2020\/7265487","article-title":"Novel Molecular Mechanisms of Pulmonary Hypertension: A Search for Biomarkers and Novel Drug Targets-From Bench to Bed Site","volume":"2020","author":"Gajecki","year":"2020","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_19","first-page":"Pi","article-title":"The pathology of primary pulmonary hypertension","volume":"101","author":"Wagenvoort","year":"1970","journal-title":"J. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1161\/01.CIR.0000102381.57477.50","article-title":"Endothelial dysfunction in pulmonary hypertension","volume":"109","author":"Budhiraja","year":"2004","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1161\/CIRCULATIONAHA.116.023171","article-title":"Metabolic Reprogramming Regulates the Proliferative and Inflammatory Phenotype of Adventitial Fibroblasts in Pulmonary Hypertension Through the Transcriptional Corepressor C-Terminal Binding Protein-1","volume":"134","author":"Li","year":"2016","journal-title":"Circulation"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.14-1678","article-title":"T-helper 17 cell polarization in pulmonary arterial hypertension","volume":"147","author":"Hautefort","year":"2015","journal-title":"Chest"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1164\/rccm.201507-1508LE","article-title":"Intrapulmonary Bronchopulmonary Anastomoses and Plexiform Lesions in Idiopathic Pulmonary Arterial Hypertension","volume":"193","author":"Galambos","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1183\/09031936.00169113","article-title":"Microvascular disease in chronic thromboembolic pulmonary hypertension: A role for pulmonary veins and systemic vasculature","volume":"44","author":"Ghigna","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e000716","DOI":"10.1161\/JAHA.113.000716","article-title":"Protein changes contributing to right ventricular cardiomyocyte diastolic dysfunction in pulmonary arterial hypertension","volume":"3","author":"Rain","year":"2014","journal-title":"J. Am. Heart Assoc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"eaao4583","DOI":"10.1126\/scitranslmed.aao4583","article-title":"Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients","volume":"9","author":"Michelakis","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCRESAHA.113.301129","article-title":"The right ventricle in pulmonary arterial hypertension: Disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure","volume":"115","author":"Ryan","year":"2014","journal-title":"Circ. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1161\/CIRCULATIONAHA.117.033147","article-title":"Right Ventricular Myofilament Functional Differences in Humans with Systemic Sclerosis-Associated Versus Idiopathic Pulmonary Arterial Hypertension","volume":"137","author":"Hsu","year":"2018","journal-title":"Circulation"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/hrt.68.7.16","article-title":"Left ventricular filling characteristics in pulmonary hypertension: A new mode of ventricular interaction","volume":"68","author":"Stojnic","year":"1992","journal-title":"Br. Heart J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1378\/chest.11-1903","article-title":"Prevalence and prognostic value of left ventricular diastolic dysfunction in idiopathic and heritable pulmonary arterial hypertension","volume":"141","author":"Tonelli","year":"2012","journal-title":"Chest"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1111\/ajt.14352","article-title":"Impact of Left Ventricular Diastolic Dysfunction on Lung Transplantation Outcome in Patients with Pulmonary Arterial Hypertension","volume":"17","author":"Avriel","year":"2017","journal-title":"Am. J. Transplant."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Hernandez-Gonzalez, I., Tenorio-Castano, J., Ochoa-Parra, N., Gallego, N., P\u00e9rez-Olivares, C., Lago-Docampo, M., Palomino Doza, J., Valverde, D., Lapunzina, P., and Escribano-Subias, P. (2021). Novel Genetic and Molecular Pathways in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease. Cells, 10.","DOI":"10.3390\/cells10061488"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijcard.2018.09.070","article-title":"Pathobiology, pathology and genetics of pulmonary hypertension: Update from the Cologne Consensus Conference 2018","volume":"272","author":"Olschewski","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.cmet.2014.08.011","article-title":"Sirtuin 3 deficiency is associated with inhibited mitochondrial function and pulmonary arterial hypertension in rodents and humans","volume":"20","author":"Paulin","year":"2014","journal-title":"Cell Metab."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1161\/CIRCULATIONAHA.117.028069","article-title":"Metabolic and Proliferative State of Vascular Adventitial Fibroblasts in Pulmonary Hypertension Is Regulated Through a MicroRNA-124\/PTBP1 (Polypyrimidine Tract Binding Protein 1)\/Pyruvate Kinase Muscle Axis","volume":"136","author":"Zhang","year":"2017","journal-title":"Circulation"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/79226","article-title":"Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension","volume":"26","author":"Lane","year":"2000","journal-title":"Nat. Genet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S2213-2600(15)00544-5","article-title":"BMPR2 mutations and survival in pulmonary arterial hypertension: An individual participant data meta-analysis","volume":"4","author":"Evans","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1161\/01.CIR.0000012754.72951.3D","article-title":"Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor","volume":"105","author":"Atkinson","year":"2002","journal-title":"Circulation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1801899","DOI":"10.1183\/13993003.01899-2018","article-title":"Genetics and genomics of pulmonary arterial hypertension","volume":"53","author":"Morrell","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1161\/CIRCRESAHA.122.321554","article-title":"BMPR2 Mutation and Metabolic Reprogramming in Pulmonary Arterial Hypertension","volume":"132","author":"Cuthbertson","year":"2023","journal-title":"Circ. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.coph.2009.02.007","article-title":"TGF-beta and BMPR-II pharmacology--implications for pulmonary vascular diseases","volume":"9","author":"Upton","year":"2009","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature02006","article-title":"Smad-dependent and Smad-independent pathways in TGF-beta family signalling","volume":"425","author":"Derynck","year":"2003","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cytogfr.2015.11.005","article-title":"Structural insights into BMP receptors: Specificity, activation and inhibition","volume":"27","author":"Yadin","year":"2016","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJM200108023450503","article-title":"Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia","volume":"345","author":"Trembath","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/thx.2003.11890","article-title":"Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension","volume":"59","author":"Chaouat","year":"2004","journal-title":"Thorax"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/jmg.2008.062703","article-title":"A new nonsense mutation of SMAD8 associated with pulmonary arterial hypertension","volume":"46","author":"Shintani","year":"2009","journal-title":"J. Med. Genet."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1164\/rccm.201906-1141OC","article-title":"Characterization of GDF2 Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension","volume":"201","author":"Hodgson","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1152\/japplphysiol.90719.2008","article-title":"Elevated levels of activin A in clinical and experimental pulmonary hypertension","volume":"106","author":"Yndestad","year":"2009","journal-title":"J. Appl. Physiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"15794","DOI":"10.1074\/jbc.M109.002881","article-title":"Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells","volume":"284","author":"Upton","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"eaaz5660","DOI":"10.1126\/scitranslmed.aaz5660","article-title":"ACTRIIA-Fc rebalances activin\/GDF versus BMP signaling in pulmonary hypertension","volume":"12","author":"Yung","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1093\/cvr\/cvaa350","article-title":"Approaches to treat pulmonary arterial hypertension by targeting BMPR2: From cell membrane to nucleus","volume":"117","author":"Dunmore","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1164\/rccm.200707-1037OC","article-title":"Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension","volume":"178","author":"Perros","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Chen, J., Cui, X., Qian, Z., Li, Y., Kang, K., Qu, J., Li, L., and Gou, D. (2016). Multi-omics analysis reveals regulators of the response to PDGF-BB treatment in pulmonary artery smooth muscle cells. BMC Genom., 17.","DOI":"10.1186\/s12864-016-3122-3"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Kudryashova, T.V., Shen, Y., Pena, A., Cronin, E., Okorie, E., Goncharov, D.A., and Goncharova, E.A. (2018). Inhibitory Antibodies against Activin A and TGF-\u03b2 Reduce Self-Supported, but Not Soluble Factors-Induced Growth of Human Pulmonary Arterial Vascular Smooth Muscle Cells in Pulmonary Arterial Hypertension. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19102957"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.celrep.2018.03.043","article-title":"Cell Autonomous and Non-cell Autonomous Regulation of SMC Progenitors in Pulmonary Hypertension","volume":"23","author":"Sheikh","year":"2018","journal-title":"Cell Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2102356","DOI":"10.1183\/13993003.02356-2021","article-title":"Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension","volume":"60","author":"Galkin","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1164\/rccm.201006-0905OC","article-title":"C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension","volume":"184","author":"Montani","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1161\/CIRCULATIONAHA.115.020951","article-title":"Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension","volume":"133","author":"Antigny","year":"2016","journal-title":"Circulation"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/j.1476-5381.2009.00283.x","article-title":"Treatment with the Kv7 potassium channel activator flupirtine is beneficial in two independent mouse models of pulmonary hypertension","volume":"157","author":"Morecroft","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Redel-Traub, G., Sampson, K.J., Kass, R.S., and Bohnen, M.S. (2022). Potassium Channels as Therapeutic Targets in Pulmonary Arterial Hypertension. Biomolecules, 12.","DOI":"10.3390\/biom12101341"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.recesp.2016.03.031","article-title":"Molecular Analysis of BMPR2, TBX4, and KCNK3 and Genotype-Phenotype Correlations in Spanish Patients and Families with Idiopathic and Hereditary Pulmonary Arterial Hypertension","volume":"69","author":"Navas","year":"2016","journal-title":"Rev. Espa\u00f1ola De Cardiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0140-6736(05)78495-6","article-title":"Attenuated K+ channel gene transcription in primary pulmonary hypertension","volume":"351","author":"Yuan","year":"1998","journal-title":"Lancet"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa1211097","article-title":"A novel channelopathy in pulmonary arterial hypertension","volume":"369","author":"Ma","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12931-020-01444-7","article-title":"In vivo miR-138-5p inhibition alleviates monocrotaline-induced pulmonary hypertension and normalizes pulmonary KCNK3 and SLC45A3 expression","volume":"21","author":"Courboulin","year":"2020","journal-title":"Respir. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"117419","DOI":"10.1016\/j.lfs.2020.117419","article-title":"Inhibition of RELM-\u03b2 prevents hypoxia-induced overproliferation of human pulmonary artery smooth muscle cells by reversing PLC-mediated KCNK3 decline","volume":"246","author":"Han","year":"2020","journal-title":"Life Sci."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Ribeuz, H.L., Courboulin, A., Ghigna, M.R., Lambert, M., Hautefort, A., Humbert, M., Montani, D., Cohen-Kaminsky, S., Perros, F., and Antigny, F. (2020). Proteomic Analysis of KCNK3 Loss of Expression Identified Dysregulated Pathways in Pulmonary Vascular Cells. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197400"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/CIRCRESAHA.119.314793","article-title":"Characterization of Kcnk3-Mutated Rat, a Novel Model of Pulmonary Hypertension","volume":"125","author":"Lambert","year":"2019","journal-title":"Circ. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e002087","DOI":"10.1161\/CIRCGEN.118.002087","article-title":"Loss-of-Function ABCC8 Mutations in Pulmonary Arterial Hypertension","volume":"11","author":"Bohnen","year":"2018","journal-title":"Circ. Genom. Precis. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"15135","DOI":"10.1038\/s41598-020-72089-1","article-title":"Characterization of rare ABCC8 variants identified in Spanish pulmonary arterial hypertension patients","volume":"10","author":"Tenorio","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/10739680600930222","article-title":"The role of k+ channels in determining pulmonary vascular tone, oxygen sensing, cell proliferation, and apoptosis: Implications in hypoxic pulmonary vasoconstriction and pulmonary arterial hypertension","volume":"13","author":"Moudgil","year":"2006","journal-title":"Microcirculation"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1161\/01.RES.0000137173.42723.fb","article-title":"Preferential expression and function of voltage-gated, O2-sensitive K+ channels in resistance pulmonary arteries explains regional heterogeneity in hypoxic pulmonary vasoconstriction: Ionic diversity in smooth muscle cells","volume":"95","author":"Archer","year":"2004","journal-title":"Circ. Res."},{"key":"ref_72","first-page":"693","article-title":"Loss of PPAR\u03b3 in endothelial cells leads to impaired angiogenesis","volume":"129","author":"Akinrinade","year":"2016","journal-title":"J. Cell Sci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.cmet.2017.03.011","article-title":"PPAR\u03b3 Links BMP2 and TGF\u03b21 Pathways in Vascular Smooth Muscle Cells, Regulating Cell Proliferation and Glucose Metabolism","volume":"25","author":"Calvier","year":"2017","journal-title":"Cell Metab."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/nm.3695","article-title":"Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension","volume":"20","author":"Savai","year":"2014","journal-title":"Nat. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1038\/s41598-017-04874-4","article-title":"HDAC6: A Novel Histone Deacetylase Implicated in Pulmonary Arterial Hypertension","volume":"7","author":"Boucherat","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1172\/JCI83361","article-title":"MicroRNA-140-5p and SMURF1 regulate pulmonary arterial hypertension","volume":"126","author":"Rothman","year":"2016","journal-title":"J. Clin. Invest."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1161\/CIRCULATIONAHA.115.019351","article-title":"Fatty Acid Metabolic Defects and Right Ventricular Lipotoxicity in Human Pulmonary Arterial Hypertension","volume":"133","author":"Brittain","year":"2016","journal-title":"Circulation"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"14079","DOI":"10.1038\/ncomms14079","article-title":"TNF\u03b1 drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling","volume":"8","author":"Hurst","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1183\/09031936.00193014","article-title":"Leptin signalling system as a target for pulmonary arterial hypertension therapy","volume":"45","author":"Huertas","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/HYPERTENSIONAHA.115.06370","article-title":"Leukotriene B4 Activates Pulmonary Artery Adventitial Fibroblasts in Pulmonary Hypertension","volume":"66","author":"Qian","year":"2015","journal-title":"Hypertension"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1172\/JCI96462","article-title":"Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension","volume":"128","author":"Tamura","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1183\/13993003.01448-2015","article-title":"Role of interleukin-1 receptor 1\/MyD88 signalling in the development and progression of pulmonary hypertension","volume":"48","author":"Parpaleix","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1164\/rccm.201408-1509OC","article-title":"Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension","volume":"192","author":"Soon","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1084\/jem.20111741","article-title":"Reduced BMPR2 expression induces GM-CSF translation and macrophage recruitment in humans and mice to exacerbate pulmonary hypertension","volume":"211","author":"Sawada","year":"2014","journal-title":"J. Exp. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"200ra117","DOI":"10.1126\/scitranslmed.3006674","article-title":"Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension","volume":"5","author":"Tian","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/jama.2022.4402","article-title":"Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review","volume":"327","author":"Ruopp","year":"2022","journal-title":"Jama"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"for the Treatment of Pulmonary Arterial Hypertension","volume":"384","author":"Humbert","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2201347","DOI":"10.1183\/13993003.01347-2022","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension","volume":"61","author":"Humbert","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"20458940211057071","DOI":"10.1177\/20458940211057071","article-title":"TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension","volume":"11","author":"Frantz","year":"2021","journal-title":"Pulm. Circ."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"386","DOI":"10.33963\/KP.15928","article-title":"Recent advances in the pharmacotherapy of pulmonary hypertension: Practical considerations","volume":"79","author":"Lareo","year":"2021","journal-title":"Kardiol. Pol."},{"key":"ref_92","unstructured":"Risbano, M.G., Frantz, R.P., Manimaran, S., Lu, J., and Rischard, F. (2021). D3 D003 Come Together\u2014Clinical Advances in Pulmonary Hypertension: Lessons from Best Abstracts, AstraZeneca."},{"key":"ref_93","unstructured":"Inc. AP (2022, December 12). A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (STELLAR), Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04576988."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nm.3877","article-title":"Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1172\/JCI65592","article-title":"FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension","volume":"123","author":"Spiekerkoetter","year":"2013","journal-title":"J. Clin. Invest."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1164\/rccm.201411-2061LE","article-title":"Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension","volume":"192","author":"Spiekerkoetter","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1602449","DOI":"10.1183\/13993003.02449-2016","article-title":"Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension","volume":"50","author":"Spiekerkoetter","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1172\/JCI24838","article-title":"Reversal of experimental pulmonary hypertension by PDGF inhibition","volume":"115","author":"Schermuly","year":"2005","journal-title":"J. Clin. Invest."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMc051946","article-title":"Imatinib for the treatment of pulmonary arterial hypertension","volume":"353","author":"Ghofrani","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1164\/rccm.201001-0123OC","article-title":"Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy","volume":"182","author":"Ghofrani","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.112.000765","article-title":"Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: Results of the randomized IMPRES study","volume":"127","author":"Hoeper","year":"2013","journal-title":"Circulation"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.healun.2015.05.025","article-title":"Long-term safety and efficacy of imatinib in pulmonary arterial hypertension","volume":"34","author":"Frost","year":"2015","journal-title":"J. Heart Lung Transplant."},{"key":"ref_103","unstructured":"Therapeutics, A. (2022, December 16). A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients with Pulmonary Arterial Hypertension (PAH), Available online: https:\/\/ClinicalTrials.gov\/show\/NCT05036135."},{"key":"ref_104","unstructured":"Therapeutics, A. (2022, December 16). Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial\u2014Follow Up Long Term Extension (IMPAHCT-FUL), Available online: https:\/\/ClinicalTrials.gov\/show\/NCT05557942."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/01.RES.0000157672.70560.7b","article-title":"Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: Efficacy of combined cell and eNOS gene therapy in established disease","volume":"96","author":"Zhao","year":"2005","journal-title":"Circ. Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1161\/CIRCRESAHA.114.305951","article-title":"Endothelial NO-Synthase Gene-Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension: The PHACeT Trial","volume":"117","author":"Granton","year":"2015","journal-title":"Circ. Res."},{"key":"ref_107","unstructured":"Therapeutics, N., and Institute OHR (2022, December 28). Study of Angiogenic Cell Therapy for Progressive Pulmonary Hypertension: Intervention with Repeat Dosing of eNOS-enhanced EPCs, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03001414."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"107423","DOI":"10.1016\/j.pharmthera.2019.107423","article-title":"Inhibition of serotonin synthesis: A novel therapeutic paradigm","volume":"205","author":"Bader","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_109","unstructured":"GmbH AS (2022, December 20). A Study of Rodatristat Ethyl in Patients with Pulmonary Arterial Hypertension (ELEVATE 2), Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04712669."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1164\/rccm.202009-3481OC","article-title":"Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial","volume":"204","author":"Zamanian","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2000314","DOI":"10.1183\/13993003.00314-2020","article-title":"IL-6 in pulmonary hypertension: Why novel is not always best","volume":"55","author":"Toshner","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.201809-1631LE","article-title":"IL-1 Blockade Reduces Inflammation in Pulmonary Arterial Hypertension and Right Ventricular Failure: A Single-Arm, Open-Label, Phase IB\/II Pilot Study","volume":"199","author":"Trankle","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_113","unstructured":"Reata Pharmaceuticals, I. (2022, December 22). Bardoxolone Methyl Evaluation in Patients with Pulmonary Hypertension (PH)\u2014LARIAT, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT02036970."},{"key":"ref_114","unstructured":"Reata Pharmaceuticals, I. (2022, December 22). Bardoxolone Methyl in Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension\u2014CATALYST, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT02657356."},{"key":"ref_115","unstructured":"Reata Pharmaceuticals, I. (2022, December 22). Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients with Pulmonary Hypertension RANGER, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03068130."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1602337","DOI":"10.1183\/13993003.02337-2016","article-title":"Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects","volume":"50","author":"Chen","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1164\/rccm.201605-1024OC","article-title":"Anastrozole in Pulmonary Arterial Hypertension. A Randomized, Double-Blind, Placebo-controlled Trial","volume":"195","author":"Kawut","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_118","unstructured":"(2022, December 26). University of Pennsylvania; National Heart, Lung, and Blood Institute (NHLBI); Johns Hopkins University; University of Colorado, Denver; Rhode Island Hospital; Stanford University; Vanderbilt University; Washington University School of Medicine Pulmonary Hypertension and Anastrozole Trial, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03229499."},{"key":"ref_119","unstructured":"Center VUM (2022, December 26). Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03528902."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1161\/CIRCULATIONAHA.113.006167","article-title":"Role for DNA damage signaling in pulmonary arterial hypertension","volume":"129","author":"Meloche","year":"2014","journal-title":"Circulation"},{"key":"ref_121","unstructured":"University L, Research CIoH, AstraZeneca (2022, December 27). Olaparib for PAH: A Multicenter Clinical Trial, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03782818."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1164\/rccm.201812-2275OC","article-title":"Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension","volume":"200","author":"Kurakula","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1164\/rccm.202109-2182LE","article-title":"BET Protein Inhibition for Pulmonary Arterial Hypertension: A Pilot Clinical Trial","volume":"205","author":"Provencher","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_124","unstructured":"Corporation OHIR (2022, December 27). Spironolactone Therapy in Chronic Stable Right HF Trial, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03344159."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cardfail.2020.10.006","article-title":"Ranolazine Improves Right Ventricular Function in Patients with Precapillary Pulmonary Hypertension: Results From a Double-Blind, Randomized, Placebo-Controlled Trial","volume":"27","author":"Han","year":"2021","journal-title":"J. Card. Fail."},{"key":"ref_126","unstructured":"Inc. AP (2022, December 30). A Study of Sotatercept in Participants with PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006\/ZENITH), Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04896008."},{"key":"ref_127","unstructured":"Inc. AP (2022, December 30). Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005\/A011-13), Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04811092."},{"key":"ref_128","first-page":"A11565","article-title":"Improvement in Cardiopulmonary Function in a Rat Model of Pulmonary Arterial Hypertension Observed with RKER-012, a Novel Activin Receptor Type II Ligand Trap, was Associated with Reduced Markers of Inflammation and Fibrosis in the Right Ventricle","volume":"146","author":"Materna","year":"2022","journal-title":"Am. Heart Assoc."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/4\/4147\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:36:20Z","timestamp":1760121380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/4\/4147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,19]]},"references-count":128,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["ijms24044147"],"URL":"https:\/\/doi.org\/10.3390\/ijms24044147","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,19]]}}}